Condition 1: Stress and anxiety levels. Condition 2: Decreased pain level. Anxiety disorder, unspecified Other specified disorders of teeth and supporting structures
Conditions
Interventions
Intervention 1: Control group (Placebo): Administration of placebo syrup (a mango juice mixture without any active drug), 30 minutes before surgery, aimed at evaluating the psychological effect of the
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: ASA physical status classification system class I & II Age 25 to 50 Non-alcoholic and non-smoking patients Candidate for implant treatment of two or more units (multiple implant placement) Patients with a score of 11 to 13 in the Modified Dental Anxiety Scale questionnaire Absence of pregnancy and breastfeeding Not taking oxycodone and hydrocodone painkillers (interference with benzodiazepines) Not using cimetidine (interference with benzodiazepines) Not taking other non-benzodiazepine sedatives
Exclusion criteria
Exclusion criteria: Suffering from systemic disease History of allergy and sensivity to certain medicine and food History of placing dental implant, zygoma and pterygoid Contraindications of benzodiazepine use (including obstructive sleep apnea, large tonsils and jaw and face anomalies)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of people whose Modified Dental Anxiety Scale score is between 11-13. Timepoint: Before administering anti-anxiety medications and 30 minutes after taking anti-anxiety medications. Method of measurement: Questionnaire: Modified Dental Anxiety Scale.;Percentage of people with pain relief 2 hours after surgery. Timepoint: 2 hours after surgery. Method of measurement: Visual Analog Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: Before drug administration: Exact timing depends on the pre-treatment protocol.30 minutes after sedative effect onset: Typically 30 minutes post-drug administration, based on the drug’s pharmacodynamics.During dental treatment: At intervals determined by the procedure’s length and complexity.During recovery: Right after the procedure and at specified intervals during post-treatment observation (e.g., every 15 or 30 minutes). Method of measurement: Digital sphygmomanometer.;Heart rate. Timepoint: Before drug administration: Exact timing depends on the pre-treatment protocol.30 minutes after sedative effect onset: Typically 30 minutes post-drug administration, based on the drug’s pharmacodynamics.During dental treatment: At intervals determined by the procedure’s length and complexity.During recovery: Right after the procedure and at specified intervals during post-treatment observation (e.g., every 15 or 30 minutes). Method of measurement: Pulse oximeter device.;Blood oxygen saturation level. Timepoint: Before drug administration: Exact timing depends on the pre-treatment protocol.30 minutes after sedative effect onset: Typically 30 minutes post-drug administration, based on the drug’s pharmacodynamics.During dental treatment: At intervals determined by the procedure’s length and complexity.During recovery: Right after the procedure and at specified intervals during post-treatment observation (e.g., every 15 or 30 minutes). Method of measurement: Pulse oximeter device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh al-Sadat Vaziri
Yazd University of Medical Sciences
Outcome results
None listed